“We continue to work toward our goal of broad access to and coverage for INPEFA, with this being the latest of a series of coverage decisions.” On May 26, 2023, the U.S. Food and Drug ...

“We have been working towards this achievement and hope to continue this momentum with additional significant progress towards broad access to and coverage for INPEFA.” On May 26 ...

I also think that Inpefa ... its payer coverage across Medicare and commercial formularies. For more clarity, a formulary is a list of prescription medications covered by a health insurance ...

The meeting runs from Oct. 16 to Oct. 19. The FDA approved Inpefa, also known as sotagliflozin, in May. The drug is approved to reduce the risk of cardiovascular death, hospitalization for heart ...

The anticipated inflection in the second half of 2024 for Inpefa sales is a key element, with expectations of expanded payor coverage and increasing physician demand. Nochomovitz recognizes the ...

“We continue to work toward our goal of broad access to and coverage for INPEFA, with this being the latest of a series of coverage decisions.” On May 26, 2023, the U.S. Food and Drug Administration ...